Agenus Inc. (NASDAQ:AGEN) Shares Acquired by Jane Street Group LLC

Jane Street Group LLC boosted its stake in shares of Agenus Inc. (NASDAQ:AGEN - Free Report) by 97.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 105,705 shares of the biotechnology company's stock after buying an additional 52,215 shares during the quarter. Jane Street Group LLC owned 0.45% of Agenus worth $290,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. B. Riley Financial Inc. acquired a new stake in shares of Agenus during the fourth quarter valued at $2,074,000. Gilead Sciences Inc. purchased a new position in Agenus in the 4th quarter valued at about $635,000. Northern Trust Corp boosted its stake in shares of Agenus by 14.8% during the 4th quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock worth $572,000 after purchasing an additional 26,870 shares during the last quarter. Bank of Montreal Can purchased a new stake in shares of Agenus during the fourth quarter worth about $69,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Agenus in the fourth quarter valued at approximately $55,000. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on AGEN shares. Robert W. Baird raised their price objective on Agenus from $4.00 to $6.00 and gave the stock a "neutral" rating in a report on Wednesday. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price target for the company in a report on Wednesday. B. Riley reaffirmed a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Finally, Wall Street Zen raised shares of Agenus from a "strong sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Agenus currently has a consensus rating of "Hold" and an average price target of $14.00.

Agenus Trading Down 8.3%

NASDAQ:AGEN traded down $0.47 during mid-day trading on Thursday, hitting $5.16. The company had a trading volume of 1,342,076 shares, compared to its average volume of 646,321. The business has a fifty day simple moving average of $2.81 and a 200-day simple moving average of $2.92. The firm has a market capitalization of $141.47 million, a price-to-earnings ratio of -0.46 and a beta of 1.48. Agenus Inc. has a 1 year low of $1.38 and a 1 year high of $18.74.

Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, topping analysts' consensus estimates of ($1.61) by $0.58. The firm had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. As a group, research analysts anticipate that Agenus Inc. will post -12.55 earnings per share for the current year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.